PCV13 vs. PPSV23: Differences in Immunity and Coverage

PCV13 and PPSV23 are both vaccines against pneumococcal disease, but they work through fundamentally different immune mechanisms and protect against different numbers of bacterial strains. PCV13 is a conjugate vaccine covering 13 serotypes of Streptococcus pneumoniae; PPSV23 is a polysaccharide vaccine covering 23 serotypes. That wider serotype coverage might make PPSV23 sound like the obvious winner, but the way PCV13 trains the immune system gives it advantages that raw numbers don’t capture, particularly in building lasting memory and reducing the bacteria’s ability to colonize the nose and throat.

How the Two Vaccines Train Your Immune System

The single biggest difference between these vaccines is what happens inside your body after you receive them. PPSV23 contains purified sugar chains (polysaccharides) from the outer coat of 23 pneumococcal serotypes. Your immune system recognizes these sugars and produces antibodies, but the response bypasses a key step: it doesn’t recruit T cells in a meaningful way. That means the antibodies you make are mostly short-lived, and your body doesn’t form strong immune memory for future encounters. PCV13, by contrast, chemically links those sugar chains to a carrier protein. That protein gives T cells something to latch onto, which kicks off a more complete immune response, producing longer-lived antibodies and memory B cells that can ramp up production again if you’re exposed later.

In practical terms, this means PCV13 generates what immunologists call a T-cell-dependent response, while PPSV23 generates a T-cell-independent one. PPSV23 tends to produce serotype-specific IgM and IgG2 antibodies but limited immune memory, whereas PCV13’s conjugate design enables enhanced immunogenicity and durable recall responses.¹ This distinction has ripple effects on almost every comparison between the two vaccines.

Serotype Coverage and What It Actually Means

On paper, PPSV23 covers far more ground. A Canadian surveillance study tracking invasive pneumococcal disease from 2011 to 2020 found that PPSV23-covered serotypes accounted for about 72% of all invasive isolates, while PCV13-covered serotypes accounted for roughly 31%.² That gap is real and matters, especially for older adults who face a broader range of circulating serotypes.

But coverage percentages don’t tell the whole story. PCV13’s conjugate mechanism produces a qualitatively stronger response against the serotypes it does cover. And because widespread childhood PCV13 vaccination has already driven down circulation of many PCV13 serotypes in the community, the practical overlap between what the vaccines cover has shifted over time. The serotypes now causing the most disease in adults are increasingly ones not in PCV13 but present in PPSV23, which partly explains why PPSV23 retained a role in adult immunization schedules for years.

Protection Against Pneumonia and Invasive Disease

The landmark clinical trial for PCV13 in adults was CAPiTA, a large Dutch study of adults aged 65 and older. It found that PCV13 reduced first episodes of vaccine-type community-acquired pneumonia by about 46%, and reduced vaccine-type invasive pneumococcal disease by 75%.³ That trial was pivotal because it showed PCV13 could prevent not just the most severe bloodstream infections but also the more common non-bacteremic pneumonia, which accounts for the majority of pneumococcal lung disease in older adults.⁴

PPSV23’s evidence base looks different. No single trial equivalent to CAPiTA exists for PPSV23 in adults. Instead, effectiveness estimates come largely from observational data. A Danish follow-up study of over 1.25 million adults aged 65 and older estimated that PPSV23 reduced all-type invasive pneumococcal disease by about 32% and PPSV23-serotype-specific invasive disease by 41%, though it found no significant protection against serotype 3.⁵ The evidence for PPSV23 against non-bacteremic pneumonia has always been weaker and more inconsistent than for PCV13.

Conjugate vaccines also appear to reduce nasal carriage of vaccine-type pneumococci, which polysaccharide vaccines do not reliably do. By cutting down colonization, PCV13 contributes to indirect (herd) protection, lowering transmission even to unvaccinated people.⁶ PPSV23 protects the individual who receives it but does little to interrupt community spread.

The Hyporesponsiveness Problem

One of PPSV23’s most clinically significant drawbacks is something called hyporesponsiveness. When you receive a second dose of PPSV23, the antibody response is often weaker than it was after the first dose, not stronger. Studies found that a second dose of PPSV23 produced a statistically significantly lower response for the majority of shared serotypes compared with the first dose.⁷ This blunted response isn’t limited to a second dose of the same vaccine. Even giving PCV13 after a prior dose of PPSV23 yields lower antibody levels than giving PCV13 to someone who has never had PPSV23, and that dampening effect persists for at least a year.⁸

The underlying reason ties back to the T-cell-independent mechanism. Polysaccharide vaccines appear to deplete the pool of memory B cells that respond to those particular sugar antigens rather than replenishing it. Repeated exposure to polysaccharide antigens can create a state of immune tolerance, leaving the body less capable of mounting a vigorous response the next time around.⁹ PCV13 doesn’t cause this problem; its conjugate design stimulates memory B cells rather than depleting them.

Why the Order of Vaccination Matters

When guidelines called for adults to receive both PCV13 and PPSV23, the recommended sequence was always PCV13 first, followed by PPSV23 at least a year later. The reasoning traces directly to the hyporesponsiveness issue. Starting with PCV13 primes the immune system through T-cell-dependent pathways, building a strong memory foundation. The subsequent dose of PPSV23 then broadens coverage to the additional serotypes without undermining the earlier immune work.

Studies in adults aged 60 to 64 confirmed that the PCV13-first sequence produced higher immune responses compared with the PPSV23-first sequence.¹⁰ Flipping the order meant that PPSV23 partially depleted the B cells PCV13 would have needed to generate its strongest response. Revaccination with PPSV23 after prior PPSV23 produced significantly lower antibody activity for the majority of tested serotypes.¹¹

This ordering effect was one reason the two-dose schedule became so complicated. The 2019 U.S. ACIP guidelines recommended a routine single dose of PPSV23 for all adults 65 and older, while PCV13 was moved to a shared clinical decision-making recommendation for that age group unless the person had specific risk factors like an immunocompromising condition. If PCV13 was chosen, it was supposed to go first, with PPSV23 following at least a year later.

How Long Does Protection Last

Antibody levels from both vaccines decline over time, but the trajectory differs. PCV13’s conjugate design is associated with longer durability of functional antibodies. In a study of kidney transplant recipients who received the PCV13-then-PPSV23 sequence, antibody concentrations remained above pre-vaccination levels five years later, with mean IgG levels roughly three times higher than baseline.¹² That said, this was in immunocompromised patients whose absolute antibody levels remained considerably lower than those of healthy people.

In immunocompromised adults more broadly, a three-year follow-up showed steep declines. Among people with HIV, the proportion meeting adequate serotype-specific responses dropped from about 44% at four months to 9% at three years. The pattern was similar in people on immunosuppressive therapy, where that proportion fell from roughly 55% to 17% over the same period. Even among healthy controls, it dropped from about 82% to 42%.¹³ These numbers reinforce the reality that neither vaccine offers permanent protection, and the question of when to revaccinate remains an active area of research.

Immunocompromised and High-Risk Adults

People with conditions like HIV, organ transplants, cancer requiring chemotherapy, or chronic diseases that suppress the immune system are at especially high risk for pneumococcal disease and were long prioritized for both vaccines. A review of available evidence found that although antibody responses to PCV13 in immunocompromised individuals were variable and generally lower than in healthy people, the vaccine was still immunogenic and well tolerated.¹⁴ In other words, the immune response is weaker than ideal, but concerns about PCV13 not working at all in these groups are not supported by the data.

One important nuance for immunocompromised patients is the boostability of the PCV13-then-PPSV23 sequence. When people with HIV or those on immunosuppressive drugs received a later booster, rapid recall responses were observed in a minority of cases, and those responses were stronger for PCV13-shared serotypes than for PPSV23-unique serotypes.¹⁵ This again underscores the advantage of conjugate technology in generating immune memory that can be reactivated, even when the initial response was modest.

Older adults face a related challenge that isn’t about disease-driven immunosuppression but about age itself. The ability to produce effective IgM antibodies declines with age, partly due to shifts in B cell populations. This age-related change may be one reason PPSV23, which depends on a T-cell-independent antibody response, appears less effective in the oldest age groups than in younger adults.¹⁶

Serotype Replacement and the Shifting Landscape

A phenomenon that complicates any vaccine comparison is serotype replacement. As childhood PCV programs dramatically reduced the circulation of vaccine-covered serotypes, other serotypes expanded to fill the ecological gap. In a study across 10 European countries, invasive disease caused by non-PCV13 serotypes climbed until it exceeded pre-vaccination era levels by over 100%.¹⁷ In England and Wales, three emerging serotypes (8, 12F, and 9N) increased rapidly and together were responsible for over 40% of all invasive pneumococcal disease cases by 2016–17, with serotype 8 alone causing a fifth of cases.¹⁸

This replacement effect shifted the balance between PCV13 and PPSV23 in a specific way. Several of the rising replacement serotypes are present in PPSV23 but not PCV13, which temporarily strengthened the case for keeping PPSV23 in the adult schedule. At the same time, the broader rise of non-vaccine serotypes underscored the limitations of both vaccines and accelerated the push toward newer conjugate vaccines with wider serotype coverage.

Side Effects

Both vaccines are generally safe and well tolerated. A Japanese study directly comparing the two found that local reactions like arm soreness and redness were somewhat more common after PCV13 (about 58% of recipients) than PPSV23 (about 45%), though reactions were mostly mild to moderate in both groups. Systemic side effects and serious adverse events were similar across both vaccines, with no treatment-related serious adverse events reported.¹⁹ The slightly higher rate of injection-site reactions with PCV13 is consistent with what’s seen in conjugate vaccines more broadly and reflects the stronger local immune activation the conjugate design produces.

The Adherence Problem With Two-Dose Schedules

One of the most underappreciated issues in the PCV13-vs-PPSV23 discussion is that many adults who were supposed to get both vaccines never completed the sequence. A population-based assessment found that concordance with the recommended pneumococcal guidelines was only about 31% for adults 65 and older and about 17% for at-risk adults aged 19 to 64.²⁰ The complexity of the schedule itself, which involved two different vaccine products separated by at least a year, with different rules depending on prior vaccination history and risk factors, was a significant barrier.

Socioeconomic status added another layer. A Belgian registry study found that people with lower socioeconomic status were less likely to complete the recommended two-dose sequence, with notably lower odds of returning for the second vaccination regardless of which vaccine was given first.²¹ This disparity meant the people who stood to benefit most from full vaccination, those with fewer health resources, were least likely to receive it.

Cost-Effectiveness Considerations

Economic analyses from different countries have generally found that adding PCV13 to a PPSV23-based strategy is cost-effective, though the degree depends on local disease burden and HIV prevalence. In South Africa, where HIV rates are high, PCV13 compared to PPSV23 alone was found to be highly cost-effective in both public and private sector settings. Among HIV-infected cohorts, PCV13 was dominant, meaning it both saved money and produced better health outcomes.²²

A South Korean analysis similarly found that the sequential PCV13-then-PPSV23 strategy was cost-effective relative to PPSV23 alone for older adults regardless of comorbidity status.²³ These findings helped build the case for conjugate-first strategies, though they also highlighted that the benefit depends heavily on how the vaccines are priced in each market and how much pneumococcal disease the local population faces.

The Move Toward Broader Conjugate Vaccines

The PCV13-vs-PPSV23 debate has largely been overtaken by the arrival of newer conjugate vaccines with expanded serotype coverage. PCV15 covers 15 serotypes and PCV20 covers 20, both using the same conjugate technology as PCV13 but reaching more of the serotypes that have been causing increasing disease through replacement. In the United States, the ACIP now recommends PCV20 or PCV15 (followed by PPSV23) over PPSV23 alone, reflecting the consensus that conjugate technology produces more durable, more functional protection.²⁴

PCV20 is particularly notable because its 20-serotype coverage comes close to closing the gap with PPSV23’s 23-serotype coverage while retaining the conjugate advantages of immune memory, boostability, and mucosal protection. For many adults, a single dose of PCV20 now replaces what used to be a complicated two-vaccine, multi-visit schedule. That simplification alone is expected to improve the adherence problems that plagued the old PCV13-then-PPSV23 approach.

Why Conjugate Manufacturing Is More Complex

One reason PPSV23 remained in wide use for so long, despite its immunological limitations, is that polysaccharide vaccines are far simpler and cheaper to produce. Making a conjugate vaccine requires chemically activating the purified polysaccharide, generating reactive groups on both the sugar chain and the carrier protein, and then linking them together. The process is inefficient: typically considerably less than 20% of the activated polysaccharide ends up conjugated, though newer methods have pushed yields closer to 50%.²⁵ Each serotype in a conjugate vaccine requires its own individual conjugation process, so moving from 13 to 20 serotypes multiplies the manufacturing complexity. PPSV23, by comparison, simply blends 23 purified polysaccharides together.

This manufacturing gap has implications for global access. In low- and middle-income countries, the higher cost and production complexity of conjugate vaccines can limit availability, even when the epidemiological case for conjugate protection is strongest. The ongoing development of conjugate vaccines with more streamlined production processes is partly aimed at narrowing that gap.

Serotype 3 and Its Stubborn Persistence

Both PCV13 and PPSV23 nominally cover serotype 3, one of the most lethal pneumococcal serotypes. Yet serotype 3 has proven stubbornly resistant to vaccine-driven control. The Danish effectiveness study found no significant PPSV23 protection against serotype 3 specifically.²⁶ And a human infection challenge study found that while PCV13 offered sustained protection against some serotypes (like 6B), its effect on serotype 3 colonization, and therefore on indirect protection through reduced transmission, was limited.²⁷

Serotype 3 produces an unusually thick polysaccharide capsule that the bacterium can shed, effectively decoy-ing antibodies away from the cell surface. This biological quirk means that even well-designed vaccines struggle to generate antibodies that can efficiently target and kill serotype 3 organisms. The persistence of serotype 3 as a major cause of severe pneumococcal disease remains one of the field’s most frustrating unsolved problems, and next-generation vaccine strategies are actively exploring ways to improve the immune response against it.